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Abstract
Background and Aims: We conducted a cohort study on the impact of obesity on disease 
activity and patient reported outcomes measurement information system (PROMIS) measures in 
the IBD Partners cohort.
Methods: We performed a cross-sectional and longitudinal study within IBD Partners, an 
internet-based cohort of >15,000 patients living with Crohn’s disease (CD) and ulcerative colitis 
(UC). We included adult patients with IBD, with recorded body mass index (BMI), with at least 6 
months of follow-up, excluding patients with BMI<18.5kg/m2. We evaluated the independent 
effect of World Health Organization classes of obesity on risk of clinical relapse or persistent 
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disease activity (using validated disease activity indices) and PROMIS measures, using 
multivariate logistic regression and linear regression, respectively.
Results: We included 7296 patients with IBD (4748 patients with CD, 19.5% obese; 2548 
patients with UC with intact colon, 20.3% obese). Obesity was independently, and in a dose-
dependent fashion, associated with increased risk of persistent disease activity or relapse in both 
patients with CD (class II or III obesity vs. normal BMI: adjusted OR, 1.86; 95% CI, 1.30–2.68) 
and UC (aOR, 2.97; 95% CI, 1.75–5.17). Obesity was also independently associated with higher 
anxiety, depression, fatigue, pain and inferior social function scores in patients with CD and UC at 
baseline, and with worsening depression, fatigue, pain and social function in patients with CD on 
longitudinal assessment.
Conclusions: Obesity at baseline is independently associated with worsening disease activity 
and PROMIS measures in patients with IBD.
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BACKGROUND
Incidence and prevalence of inflammatory bowel diseases (IBD) is rising in parallel with the 
global obesity epidemic. Approximately 15–40% of adult patients with IBD are obese (body 
mass index [BMI] ≥30 kg/m2).(1) Obesity has been variably associated with IBD phenotype, 
with some studies suggesting milder disease and others suggesting lower prevalence of 
remission in cross-sectional studies.(1–4) There are conflicting data on how obesity may 
impact outcomes in patients with IBD, with some studies showing inferior quality of life and 
higher healthcare utilization, whereas others showing no significant difference in the risk of 
IBD-related surgery, hospitalization or emergency department use in obese vs. overweight 
vs. normal BMI adults.(4–8) Obesity has also been shown to negatively impact response to 
biologic therapy in patients with ulcerative colitis (UC) and other immune-mediated 
diseases, but this observation has been inconsistent.(9, 10)
However, most single-center studies have a small sample size, low event rate, and have 
relied on retrospective physician global assessment or non-validated indices, rather than 
patient-reported outcomes (PROs), to assess impact of obesity on clinical activity; none have 
systematically evaluated it’s impact on patient reported outcomes measurement information 
system (PROMIS) measures in IBD.
Hence, we performed secondary analysis of a prospectively maintained internet-based cohort 
of >15,000 patients with IBD, IBD Partners, to evaluate the association between obesity and 
clinical disease activity (risk of relapse in a subset of patients in remission at baseline, and 
risk of persistently active disease in patients with active disease at baseline) and PROMIS 
measures (at baseline, and follow-up).
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We performed a cross-sectional and longitudinal study within the Crohn’s and Colitis 
Foundation’s IBD Partners cohort. The study cohort has been described in detail previously.
(11, 12) Briefly, patients were recruited to enroll in this online cohort registry via a variety 
of means, including invitations via email, social media, and recruitment at the Crohn’s and 
Colitis Foundation educational events. Over 15,000 patients with self-reported IBD have 
enrolled in the cohort since initiation in 2011, and cohort members are followed up at 6-
month intervals. Baseline and follow up surveys include a core survey with information on 
disease phenotype, activity, medication use, and patient-reported outcomes.
From this cohort, we included (1) patients with IBD (CD or UC), (2) recorded data on body 
mass index (BMI) at baseline, and (3) at least 6 months of follow-up (i.e., filling a follow-up 
survey). When data was available at multiple time points, then outcomes at 12 months, 18 
months or 6 months were used, in that order; if only one time point measure was available, 
then that time point was used for outcome assessment. We excluded patients who were 
underweight (BMI<18.5 kg/m2) (due to potential confounding by disease severity impacting 
nutritional status), had end-ileostomy or ileoanal pouch (as disease activity indices are not 
validated in these specific sub-populations).
Exposure
The primary predictor variable was BMI, based on patient self-reported weight and height, 
categorized based on World Health Organization obesity classes as: normal BMI (BMI 18.5–
24.9 kg/m2, reference), overweight (BMI 25.0–29.9 kg/m2), class I obesity (BMI 30.0–34.9 
kg/m2) and class II/III obesity (BMI 35.0–39.9 kg/m2). In addition, BMI was also 
categorized as a continuous variable, evaluating the association between each 1 kg/m2 
increase in BMI and clinical outcomes.
Outcomes
There were two primary outcomes in the study: (1) clinical disease activity, measured using 
short Crohn’s disease activity index (sCDAI) in patients with CD and simple clinical colitis 
activity index (SCCAI) in patients with UC,(13, 14) and (2) PROMIS measures, for anxiety, 
depression, fatigue, sleep disturbance, satisfaction with social role, and pain interference. Of 
note, sCDAI is based on abdominal pain, diarrhea frequency, and general well-being, and 
unlike full CDAI, does not include weight as a variable.
Clinical disease activity: In the cross-sectional analysis, presence of active disease was 
defined as sCDAI >150 (CD) or SCCAI >2 (UC). In the longitudinal analysis, active disease 
was defined as clinical relapse at follow-up survey (development of active disease, in the 
subset of patients in remission at baseline) or having persistent disease activity (in the subset 
of patients with active disease at baseline).
PROMIS measures: The PROMIS® initiative of the National Institutes of Health was 
developed to advance the science and application of patient-reported outcomes among 
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patients with chronic diseases for use in research and clinical practice.(15) PROMIS 
instruments are general (not disease-specific) measures that are valid and responsive, allow 
comparisons within and between conditions, and are grouped into item banks based on 
symptoms, function, well-being, and general health. PROMIS items are calibrated using a T-
score metric with the mean of the US general population equal to 50 and standard deviation 
(SD) in the general population equal to 10.(15) Minimal Important Differences (MIDs), the 
score that is large enough to have implications for a patient’s treatment or care, was deemed 
to be 2.5.(16) Higher scores indicate more of the domain being measured, such that high 
scores for anxiety, depression, fatigue, sleep disturbance, and pain interference indicate 
poorer health, whereas high scores for satisfaction with social role indicate better health. In 
the cross-sectional analysis, difference in T-score of PROMIS measures was measured 
between different categories of BMI. In the longitudinal analysis, the association between 
obesity and change in PROMIS measure over time was measured.
Covariates
Covariates of interest included: disease duration, smoking status (stratified as never, past, 
and current smoking at the time of baseline questionnaire), ethnicity, education status, self-
reported IBD-related hospitalization or surgery, as well as medications for treatment of IBD 
including 5-aminosalicylates (oral), corticosteroids (oral), immunomodulators, and biologic 
therapies (infliximab, adalimumab, certolizumab pegol, and natalizumab), and narcotic use. 
Post-hoc, we also included change in BMI class at follow-up as a covariate. We also 
evaluated interaction between BMI and age, sex, smoking, college education, race, prior 
surgery, prior hospitalization, disease duration, biologic therapy, immunomodulator therapy, 
corticosteroids, 5-aminosalicylate therapy and narcotic use, in both patients with Crohn’s 
disease and ulcerative colitis.
Statistical Analysis
All analyses were stratified by CD and UC.
Clinical disease activity:  In the cross-sectional analysis, we compared the unadjusted 
prevalence of remission across BMI categories using univariable logistic regression. In the 
longitudinal analysis, the association between BMI categories and risk of active disease was 
analyzed using multivariable logistic regression analysis. In this analysis, all key covariates 
were included in univariable analysis, and all baseline variables with a p-value<0.20 were 
included in the multivariable model, using backward model selection approach. In the 
longitudinal cohort, stratified analysis by patients in remission vs. active disease at baseline 
was performed. Dose-response relationship between BMI and clinical disease activity was 
analyzed using logistic regression analysis, for increase in BMI category.
PROMIS Measures:  In the cross-sectional analysis, we compared the T-scores for each 
PROMIS item at baseline across BMI categories, both unadjusted using analysis of variance 
(ANOVA) and after adjustment for key covariates including baseline medication use, disease 
activity, etc., using linear regression with ANOVA F test to analyze for significant variability 
across categories. In the longitudinal analysis, we compared magnitude of change from 
baseline T-score for each item across BMI categories using multivariable linear regression, 
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after adjusting for key covariates, including baseline PROMIS score. As noted above, MID 
for PROMIS items was assigned as 2.5.
All hypothesis testing was performed using a two-sided p-value with a statistical 
significance threshold <0.05. All statistical analyses were performed with Stata MP 
(StataCorp. 2015. Stata Statistical Software: Release 14. College Station, TX: StataCorp 
LP). IBD Partners’ study protocol was approved by the Institutional Review Board at the 
University of North Carolina, Chapel Hill, North Carolina; this secondary analysis of 
previously collected data was deemed exempt by the University of California San Diego 
Institutional Review Board.
RESULTS
We included 7296 patients with IBD in our analysis. The number of patients with follow-up 
at 6, 12 and 18 months was 2074, 6056 and 7018, respectively. On follow-up at 12 months, 
across baseline BMI categories, 78.3%−91.2% remained in their respective BMI categories 
at 12 months (eTable 1). Among patients with change in BMI, most moved up or down one 
category; <0.5% moved up or down 2 categories (except 2% patients with baseline class II 
or III obesity, who had BMI at follow-up <30kg/m2).
Crohn’s Disease
We included 4748 patients with CD in our analysis, of whom 19.5% were classified as 
obese. Baseline demographics and clinical features of CD patients, stratified by BMI 
category are shown in Table 1. As compared to patients with normal BMI, obese patients 
were marginally older, more likely to be female, less likely to have college education, more 
likely to be current smokers, less likely to have had prior surgery, and were more likely to be 
on narcotics, in this cohort. The prevalence of use of 5-aminosalicylates, 
immunomodulators, biologic agents and corticosteroids was comparable across BMI 
categories; of note, <10% of the cohort was on corticosteroids at time of baseline evaluation.
Clinical disease activity: At baseline, the prevalence of clinical remission was lower in 
obese patients as compared to patients with normal BMI, with an exposure-response 
relationship (p<0.01) (Figure 1). On longitudinal analysis, obese patients were more likely to 
have active disease on follow-up, as compared to patients with normal BMI, with an 
exposure-response relationship (Figure 2). After adjustment for covariates, patients with 
overweight, class I and class II/III obesity had 39%, 50% and 86% higher odds of having 
active disease at follow-up as compared to patients with normal BMI, respectively (Table 2). 
Each 1 kg/m2 increase in BMI was associated with a 3% higher odds of having active 
disease. When analysis was restricted to patients in clinical remission at baseline, higher risk 
of relapse was observed in obese patients vs. patients with normal BMI (obese vs. normal 
BMI: OR, 1.31; 95% CI, 1.00–1.73, p=0.049). Similar results were obtained when analysis 
was restricted to patients with active disease at baseline. No significant interactions were 
observed, except race and BMI in CD – African American patients with class I/II/III obesity 
had higher risk, as compared to Caucasians with class I/II/III obesity.
Jain et al. Page 5













PROMIS Measures: Mean baseline PROMIS scores for anxiety, depression, fatigue, sleep 
disturbance, satisfaction with social role, and pain interference, by BMI categories are 
shown in Table 1. Across all items, except sleep disturbance, overall scores were inferior in 
obese patients as compared to patients with normal BMI (p<0.001), though we did not 
specifically evaluate differences in PROMIS measures across pre-defined individual 
categories of obesity. After adjustment for covariates including baseline disease activity, 
these differences were higher than the MIDs for all items (except sleep disturbance) in 
patients with class II/III obesity vs. normal BMI (MIDs ranging from 2.14 to 5.02) (eTables 
2–7). On longitudinal analysis, after adjustment for covariates including baseline item 
scores, obese patients had a significantly greater magnitude of decline in PROMIS item 
scores for depression (change in T-score, class II/III obesity vs. normal BMI: 1.15), fatigue 
(1.52), pain interference (1.33) and satisfaction with social role (−1.62); however, these did 
not meet thresholds for MID.
Ulcerative Colitis
We included 2548 patients with UC in our analysis, of whom 20.3% were classified as 
obese. Baseline demographics and clinical features of UC patients, stratified by BMI 
category are shown in Table 3. As compared to patients with normal BMI, obese patients 
were marginally older, less likely to have college education and were more likely to be on 
narcotics; there was no difference in the prevalence of use of 5-aminosalicylates, 
immunomodulators, biologic agents and corticosteroids across BMI categories.
Clinical disease activity: At baseline, the prevalence of clinical remission was lower in 
obese patients as compared to patients with normal BMI, with an exposure-response 
relationship (p<0.01) (Figure 1). On longitudinal analysis, obese patients were more likely to 
have active disease on follow-up, as compared to patients with normal BMI, with an 
exposure-response relationship (Figure 3). After adjustment for covariates, patients with 
class I and class II/III obesity had 65% and 197% higher odds of having active disease at 
follow-up as compared to patients with normal BMI, respectively (Table 4). Each 1 kg/m2 
increase in BMI was associated with a 5% higher odds of having active disease. When 
analysis was restricted to patients in clinical remission at baseline, 40.3% and 27.3% 
patients with class II/III and class I obesity experienced relapse, respectively, as compared to 
21.7% patients with normal BMI (p<0.01). After adjustment for covariates, patients with 
class II/III obesity had 2.4 times higher odds of relapse as compared to patients with normal 
BMI (adjusted OR, 2.41; 95% CI, 1.40–4.17). Similar results were obtained when analysis 
was restricted to patients with active disease at baseline. No significant interactions between 
BMI and covariates were observed.
PROMIS Measures: Mean baseline PROMIS scores for anxiety, depression, fatigue, sleep 
disturbance, satisfaction with social role, and pain interference, by BMI categories are 
shown in Table 3. As noted for CD, across all items, except sleep disturbance, overall scores 
were inferior in obese patients with UC as compared to patients with normal BMI (p<0.001), 
though we did not specifically evaluate differences in PROMIS measures across pre-defined 
individual categories of obesity. After adjustment for covariates including baseline disease 
activity, these differences were higher than the MIDs for all items (except fatigue, MID 
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1.74) in patients with class II/III obesity vs. normal BMI (MIDs ranging from −3.20 to 4.01) 
(eTables 8–13). On longitudinal analysis, after adjustment for covariates including baseline 
item score, obese patients had a significantly greater magnitude of decline in PROMIS item 
scores for pain interference (change in T-score, class II/III obesity vs. normal BMI: 2.97), 
though they experienced a marginal improvement in sleep disturbance (−0.74).
DISCUSSION
In this secondary analysis of prospectively collected data on >7000 patients with IBD from 
an internet-based cohort, ~20% of whom were obese, we made several key observations. 
First, both patients with CD and UC with obesity at baseline had significantly lower 
prevalence of clinical remission, and inferior scores on multiple PROMIS domains including 
anxiety, depression, fatigue, satisfaction with social role, and pain interference, as compared 
to patients with normal BMI, with an exposure-response relationship. Second, on 
longitudinal analysis over the course of 12 months, obese patients with CD and UC had 
higher risk of having active disease, including higher risk of relapse (among patients in 
remission at baseline) and persistently active disease (among patients with active disease at 
baseline), as compared to patients with normal BMI. The magnitude of this effect appears 
stronger in patients with UC, as compared to patients with CD. Third, obese patients, 
particularly those with CD, experienced worsening across multiple PROMIS domains on 
longitudinal analysis, as compared to patients with normal BMI. However, these differences 
did not meet thresholds of MID, and clinical significance of these findings is unclear. 
Overall, these findings suggest that obesity significantly impacts disease-specific patient-
reported clinical activity and disease-agnostic patient-reported outcomes, both at baseline 
and on longitudinal follow-up over the course of 12 months. In conjunction with evolving 
findings on the impact of obesity on increased healthcare utilization, and higher risk of 
hospitalization, surgery and biologic treatment failure, especially in patients with UC, these 
findings firmly identify obesity as a negative prognostic factor in patients with IBD.(5, 9, 10) 
This has important potential clinical implications. Physicians should be cognizant of this 
association between obesity and adverse IBD outcomes, and should closely monitor these 
patients and consider early optimization of therapy.
Obesity is recognized as a perpetual state of chronic low-grade inflammation, through 
systemic and paracrine increase in levels of cytokines, chemokines and adipokines, and is 
also associated with dysbiosis.(1) Obesity increases leptin secretion from adipocytes and 
resistin secretion from macrophages and leukocytes that increase levels of pro-inflammatory 
cytokines such as tumor necrosis factor, interleukin-1 and −6.(17) In addition to its direct 
impact on inflammation, obesity can also modify pharmacokinetics of biologic agents, 
resulting in rapid drug clearance.(18) Hence, obesity could adversely affect both 
inflammatory burden in IBD, as well as response to medical therapy.
While obesity has been consistently shown to negatively impact clinical disease activity and 
treatment response to biologic agents in immune-mediated inflammatory diseases, this 
evidence has been inconsistent in patients with IBD to date.(9) There have been a limited 
number of conflicting longitudinal studies on the impact of obesity on disease course in 
IBD. Seminerio and colleagues observed inferior IBD-related quality of life and higher 
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frequency of elevated levels of serum C-reactive protein in patients with obesity (particularly 
class II or III obesity) compared with normal weight patients; however, there was no 
statistically significant difference in the risk of IBD-related surgery, hospitalization or 
emergency department use between patients who were obese, overweight or a normal BMI.
(4) In contrast, Flores and colleagues observed a lower risk of IBD-related surgery (41% 
versus 52% versus 61% for patients who were obese, overweight, or normal or underweight, 
respectively), hospitalization (42% versus 44% versus 66%) and initiation of anti-TNF 
therapy (25% versus 26% versus 43%), both in patients with CD and UC.(2) How obesity 
impacts clinical disease activity and patient-reported outcomes in patients with IBD has not 
been well studied. To understand the impact of obesity on the natural history of IBD in a 
controlled setting, we had previously conducted a post-hoc analysis of 4 placebo-controlled 
trials of infliximab in adults with moderate-severe IBD. In 575 placebo-treated patients in 
these trials, we did not observed any association between BMI and odds of achieving clinical 
remission or mucosal healing, measured using validated clinical disease activity indices.(8) 
However, in these trials, follow-up was short, and proportion of patients with class II/III 
obesity was small, which limited meaningful inferences on the impact of morbid obesity on 
clinical activity in IBD. Moreover, this study did not evaluate the impact of obesity on 
PROMIS measures. This void was filled by the current study, where by using a large 
internet-based cohort of patients with IBD, with follow-up over 12 months, using validated 
patient-reported disease-related activity indices as well as disease-agnostic PROMIS 
measures, we observed a clear negative association between obesity and patient-reported 
outcomes across multiple domains.
Our findings provide potential directions for future research. While small RCTs and cohort 
studies in patients with psoriasis, psoriatic arthritis and rheumatoid arthritis have suggested a 
beneficial effect of intentional weight loss on treatment response to anti-TNF agents, it is 
unclear whether such a therapeutic intentional weight loss may improve outcomes in patients 
with IBD, and merits evaluation.(19–21). Additionally, future clinical trials should consider 
obesity as a potential effect modifier, and consistently report stratified analyses.
There are several strengths to the current study. This is the largest study to date investigating 
impact of obesity on patient-reported outcomes in patients with IBD. The IBD Partners 
cohort includes patients cared for in a variety of settings including academic and community 
centers. We believe this real-world cohort, in which 20% of participants were obese 
(including 8% patients with class II/III obesity), is more representative, than evidence from 
post-hoc analyses of clinical trials on the natural history of disease. This diverse distribution 
of BMI in the cohort also helped confirm presence of an exposure-response relationship. 
Additionally, we used validated self-reported clinical disease activity indices and PROMIS 
measures, which makes the study more rigorous. Observing consistent findings across both 
disease-specific and disease-agnostic measures, after adjusting for key relevant variables, 
and the presence of an exposure-response relationship, make these findings more 
biologically plausible.
Nonetheless, there are some key limitations. First, we relied on patient self-report of weight 
and height to estimate BMI. Given the simplicity of these measurements and the large 
sample size of the current study, systematic errors in reporting BMI is less likely; 
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nonetheless, future studies should evaluate should involve systematic objective assessment 
of both overall obesity and central adiposity in patients with IBD.(22) Second, while IBD 
Partners has notable strengths in recruitment and retention, the dataset may not be truly 
representative of a population of IBD patients, including a higher percentage of female 
patients (>70%), Caucasian race (>90%) and higher rates of college education than national 
averages. Third, the IBD Partners cohort does not include physician notes, laboratory, 
radiology or endoscopy data. Hence, we were unable to corroborate our findings with 
simultaneous assessment of impact of obesity on biochemical and/or endoscopic remission. 
Fourth, we also do not have validated data on disease phenotype, disease location or extent 
in this cohort, limiting detailed analyses of how obesity may impact disease activity across 
these strata. Finally, we were unable to evaluate stability of BMI at baseline assessment; 
however, as noted, on follow-up, proportion of patients with significant change in BMI was 
small. Likewise, prior medication exposure or change in medication exposure on follow-up 
could not be systematically analyzed.
In conclusion, based on a large internet-based cohort study of >7000 patients with IBD, we 
observed a strong and consistent association between obesity and lower rates of clinical 
remission and inferior PROMIS measures on cross-sectional and longitudinal analyses, in 
both patients with CD and UC. Among patients in remission at baseline, obesity was 
associated with increased risk of relapse, with stronger associations in patients with UC. 
Prospective cohort studies, including objective measures of overall obesity and central 
adiposity and disease activity, are warranted to confirm this association.
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WHAT IS CURRENT KNOWLEDGE?
• Approximately 15–40% patients with IBD are obese
• Obesity has been variably associated with IBD phenotype, with some cross-
sectional studies suggesting milder disease and others suggesting lower 
prevalence of remission
• There are conflicting data on how obesity may impact outcomes in patients 
with IBD
WHAT IS NEW HERE?
• In a large internet-based cohort of patients with IBD, obesity was 
independently associated with persistent disease activity (in patients with 
active disease at baseline) and relapse (in patients in clinical remission at 
baseline) in patients with ulcerative colitis and Crohn’s disease, in a dose-
dependent manner
• Obesity was also independently associated with higher anxiety, depression, 
fatigue, pain and inferior social function scores in patients with Crohn’s 
disease and ulcerative colitis
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Proportion of patients in clinical remission at baseline, based on body mass index
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Impact of obesity on clinical disease activity in patients with Crohn’s disease on longitudinal 
follow-up: (A) proportion of patients with active disease, regardless of baseline disease 
activity, (B) proportion of patients with relapse in subset of patients in remission at baseline, 
(C) proportion of patients with persistent disease activity in subset of patients with active 
disease at baseline
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Impact of obesity on clinical disease activity in patients with ulcerative colitis on 
longitudinal follow-up: (A) proportion of patients with active disease, regardless of baseline 
disease activity, (B) proportion of patients with relapse in subset of patients in remission at 
baseline, (C) proportion of patients with persistent disease activity in subset of patients with 
active disease at baseline
Jain et al. Page 16

























Jain et al. Page 17
Table 1.
Baseline characteristics of patients with Crohn’s disease, by body mass index




kg/m2) (n = 1331)
Class I Obesity 
(30–34.9 kg/m2) (n 
= 541)
Class II or III 
Obesity (≥35.0 
kg/m2) (n = 385)
P-value
Age, mean (SD) 41.5 ± 15.5 45.8 ± 14.6 45.4 ± 13.6 44.7 ± 12.4 <0.01
Disease duration, median in 
years (range)
11 (4 – 22.5) 12 (5 – 23) 11 (4 – 20) 10 (4 – 18) <0.01
Gender (% female) 74.3% 62.6% 80.4% 85.2% <0.01
Education (% with college 
degree)
72.3% 70.5% 69.4% 61.5% <0.01
Race
  Caucasian 95.5% 95.1% 94.2% 92.1% 0.003
  African American 1.0% 1.8% 2.1% 3.8%
  Asian 0.7% 0.6% 0.2% 0%
  Other 2.8% 2.5% 3.5% 4.1%
Prior abdominal surgery (%) 51.0% 49.3% 44.0% 46.0% 0.02
Prior hospitalization 74.7% 73.2% 71.5% 72.2% 0.36
Smoking (current, % yes) 7.4% 7.2% 8.7% 11.4% 0.03
Baseline Medications
5-aminosalicylates 18.1% 19.8% 20.5% 19.2% 0.44
Steroids 7.5% 6.9% 7.2% 9.1% 0.55
Immunomodulator 20.6% 20.5% 17.4% 22.3% 0.26
Biologics 33.5% 34.2% 33.5% 35.1% 0.92
Narcotics 5.0% 6.1% 9.4% 9.1% <0.01
Baseline PROMIS Measures
Anxiety 51.59 (9.50) 51.57 (9.47) 52.72 (9.78) 54.65 (10.33) <0.01
Depression 49.60 (9.11) 50.04 (9.23) 51.81 (9.27) 53.93 (10.34) <0.01
Fatigue 53.74 (10.84) 54.73 (10.92) 58.11 (10.70) 60.40 (10.35) <0.01
Pain 50.52 (9.43) 51.12 (9.72) 54.08 (9.96) 56.39 (10.35) <0.01
Sleep 52.04 (3.27) 51.86 (3.43) 51.89 (3.57) 52.22 (3.40) 0.20
Social satisfaction 50.34 (9.89) 49.60 (9.70) 46.85 (9.66) 44.54 (9.44) <0.01
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Table 2.
Factors associated with active disease at follow-up in patients with Crohn’s Disease, regardless of baseline 
disease activity, on multivariable logistic regression analysis
Predictor Variables Odds Ratio (95% Confidence Interval) p-value
BMI
  • Normal
  • Overweight (25–29.9)
  • Class I obesity
  • Class II or III obesity
1.0
1.39 (1.08 – 1.78)
1.50 (1.07 – 2.09)




Female gender (vs. male) 1.71 (1.34 – 2.21) <0.01
College education 0.72 (0.57 – 0.90) <0.01
African American versus Caucasian 1.29 (0.61 – 2.68) 0.50
Other ethnicities versus Caucasian 1.59 (0.92 – 2.70) 0.09
History of prior surgeries 1.73 (1.35 – 2.22) <0.01
History of prior hospitalization 1.11 (0.84 – 1.48) 0.47
Current smoking status 2.21 (1.54 – 3.20) <0.01
Immunologic therapy at baseline 0.94 (0.73 – 1.23) 0.67
Narcotic use at baseline 2.56 (1.73 – 3.83) <0.01
5-ASA therapy at baseline 0.75 (0.57 – 0.99) 0.04
Steroid use at baseline 1.35 (0.88 – 2.05) 0.16
Biologic use at baseline 0.87 (0.69 – 1.09) 0.23
Age (per 1 y increase) 1.00 (0.99 – 1.01) 0.70
Disease duration (per 1y increase) 1.00 (0.99 – 1.01) 0.83
Change in BMI category
  • 1 category increase
  • 1 category decrease
0.90 (0.59 – 1.35)
0.76 (0.48 – 1.18)
0.60
0.23
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Table 3.
Baseline characteristics of patients with ulcerative colitis, by body mass index




kg/m2) (n = 752)
Class I Obesity 
(30–34.9 kg/m2) (n 
= 304)
Class II or III 
Obesity (≥35.0 
kg/m2) (n = 213)
P-value
Age, mean (SD) 41.3 ± 14.7 46.4 ± 14.7 47.4 ± 14.3 47.3 ± 12.9 <0.01
Disease duration, median in 
years (range)
7 (3 – 14) 9 (3 – 18) 7 (3 – 15) 8 (3 – 17) 0.01
Gender (% female) 74.1% 60.5% 69.4% 84.1% <0.01
Education (% with college 
degree)
79.3% 74.8% 65.4% 64.1% <0.01
Race
  Caucasian 92.4% 93.8% 91.7% 93.7% 0.13
  African American 1.2% 1.3% 2.4% 2.9%
  Asian 2.6% 1.3% 2.1% 0%
  Other 3.8% 3.8% 3.8% 3.4%
Prior hospitalization 41.8% 39.9% 38.8% 44.9% 0.45
Smoking (current, % yes) 4.1% 2.9% 5.3% 2.8% 0.24
Baseline Medications
5-aminosalicylates 43.4% 46.7% 44.9% 46.7% 0.47
Steroids 6.6% 6.5% 7.6% 9.8% 0.34
Immunomodulator 16.0% 16.8% 19.8% 14.5% 0.36
Biologics 21.6% 18.5% 19.5% 17.3% 0.25
Narcotics 1.8% 2.5% 4.6% 6.5% <0.01
Baseline PROMIS Measures
Anxiety 51.54 (9.16) 50.58 (9.16) 52.74 (9.88) 54.05 (9.55) <0.01
Depression 49.07 (8.66) 49.24 (8.67) 51.57 (9.98) 53.58 (9.82) <0.01
Fatigue 51.75 (11.02) 52.28 (10.75) 55.48 (10.65) 57.97 (10.78) <0.01
Pain 49.03 (9.11) 50.37 (9.46) 52.30 (10.07) 55.36 (10.07) <0.01
Sleep 52.01 (3.30) 51.90 (3.53) 52.28 (3.58) 52.33 (3.60) 0.24
Social satisfaction 51.23 (9.92) 50.63 (10.14) 48.12 (9.64) 46.03 (10.07) <0.01
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Table 4.
Factors associated with active disease at follow-up in patients with ulcerative colitis, regardless of baseline 
disease activity, on multivariable logistic regression analysis
Predictor Variables Odds Ratio (95% Confidence Interval) p-value
BMI
  • Normal
  • Overweight (25–29.9)
  • Class I obesity
  • Class II or III obesity
1.0
1.03 (0.75 – 1.42)





Female gender 1.14 (0.84 – 1.54) 0.41
College education 0.73 (0.53 – 1.00) 0.05
African American vs. Caucasian 0.88 (0.28 – 2.64) 0.82
Other ethnicities vs. Caucasian 1.65 (0.92 – 2.99) 0.09
History of prior hospitalization 1.55 (1.16 – 2.07) <0.01
Current smoking status 1.62 (0.76 – 3.57) 0.22
Immunologic therapy at baseline 0.56 (0.37 – 0.83) <0.01
5-ASA therapy at baseline 0.81 (0.61 – 1.08) 0.15
Narcotic use at baseline 1.67 (0.75 – 3.95) 0.22
Steroid use at baseline 2.26 (1.30 – 4.01) <0.01
Biologic use at baseline 1.12 (0.79 – 1.60) 0.53
Age (per 1y increase) 1.00 (0.99 – 1.01) 0.64
Disease duration (per 1y increase) 1.00 (0.98 – 1.01) 0.67
Change in BMI category
  • 1 category increase
  • 1 category decrease
0.63 (0.36 – 1.09)




Additionally adjusted for age, disease duration, African American versus Caucasian, Other ethnicities versus Caucasian, and biologic therapy at 
baseline.
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